| Literature DB >> 35451705 |
Malin Sjöström1, M Arvidsson2, L Söderström3, M Lilja4, J Lindh5, M Widerström2.
Abstract
In 2010-2011, a waterborne outbreak of the parasite, Cryptosporidium hominis, affected approximately 27,000 inhabitants in the city of Östersund, Sweden. Previous research suggested that post-infectious symptoms, such as gastrointestinal symptoms and joint pain, could persist for up to 2 years after the initial infection. In this study, we investigated whether the parasite caused post-infectious sequelae for up to 5 years after the outbreak. Prospective cohort study. A randomly selected cohort of individuals residing in Östersund at the time of the outbreak was sent a postal questionnaire in 2011. Responders were sent a follow-up questionnaire in 2016 and completed items on whether they experienced a list of symptoms. We examined whether outbreak cases were more likely than non-cases to report post-infectious symptoms 5 years later. We analysed data using logistic regression and calculated odds ratios with 95% confidence intervals. The analysis included 626 individuals. Among the 262 individuals infected during the outbreak, 56.5% reported symptoms at follow-up. Compared to non-cases, outbreak cases were more likely to report watery diarrhoea, diarrhoea, swollen joints, abdominal pain, bloating, joint discomfort, acid indigestion, alternating bowel habits, joint pain, ocular pain, nausea, and fatigue at the follow-up, after adjusting for age and sex. Our findings suggested that cryptosporidiosis was mainly associated with gastrointestinal- and joint-related post-infectious symptoms for up to 5 years after the infection.Entities:
Keywords: Cryptosporidium; Diarrhoea; Disease outbreaks; Post-infectious symptoms; Sequelae
Mesh:
Year: 2022 PMID: 35451705 PMCID: PMC9192462 DOI: 10.1007/s00436-022-07524-5
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.383
Fig. 1Flow chart of the case selection process. Case = new episodes of diarrhoea (≥ 3 episodes daily), and/or watery diarrhoea between November 1, 2012, and January 31, 2011, in respondent residing in Östersund in mid-January 2011. Non-case = any respondent not fulfilling the case criteria during the outbreak. IBD, inflammatory bowel disease; IBS, irritable bowel syndrome
Demographic characteristics of the study population, grouped by outbreak case status
| Characteristic | Case | Non-case | Total |
|---|---|---|---|
| Sex | |||
| Female | 145 (55.3) | 201 (55.2) | 346 (55.3) |
| Male | 117 (44.7) | 163 (44.8) | 280 (44.7) |
| Age group, y (at outbreak) | |||
| 0–15 | 44 (16.8) | 50 (13.7) | 94 (15.0) |
| 16–40 | 72 (27.5) | 68 (18.7) | 140 (22.4) |
| 41–65 | 109 (41.6) | 152 (41.8) | 261 (41.7) |
| > 65 | 37 (14.1) | 94 (25.8) | 131 (20.9) |
| Total cases | 262 | 364 | 626 |
Symptoms reported at follow-up by respondents and associations with case status
| Symptom | Total | 0–15 years | 16–40 years | 41–65 years | > 65 years | ||
|---|---|---|---|---|---|---|---|
| Cases | Non-cases | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Watery diarrhoea | 43 (16.8) | 14 (4.0) | 2.5 (0.9–7.0) | ||||
| Diarrhoea | 52 (20.2) | 23 (6.4) | 3.7 (0.7–19.4) | 2.4 (1.0–6.1) | 5.7 (1.0–34.0) | ||
| Swollen joints | 33 (12.9) | 20 (5.8) | 7.5 (0.9–63.4) | 2.7 (0.9–8.1) | |||
| Abdominal pain | 64 (25.1) | 36 (10.1) | 2.0 (0.8–5.0) | 2.0 (0.9–4.5) | 3.7 (0.7–8.1) | ||
| Bloating | 102 (39.4) | 73 (20.9) | 2.8 (0.8–8.2) | 2.1 (1.0–4.3) | |||
| Joint discomfort | 82 (31.8) | 62 (17.7) | 2.7 (0.7–9.6) | 1.7 (0.7–3.9) | |||
| Stiff joints | 71 (27.5) | 58 (16.7) | 2.2 (0.4–13.0) | 1.2 (0.5–2.9) | |||
| Acid indigestion | 62 (23.9) | 44 (12.8) | 4.7 (0.9–24.2) | 1.9 (0.8–4.6) | 1.8 (0.9–3.3) | ||
| Changes in bowel habits | 47 (18.1) | 32 (9.3) | 2.9 (0.7–11.9) | 2.5 (0.9–7.0) | 1.5 (0.8–3.0) | ||
| Joint pain | 79 (30.4) | 65 (18.7) | 1.8 (0.5–7.0) | 0.8 (0.3–2.0) | |||
| Ocular pain | 49 (19.3) | 33 (9.5) | 2.4 (0.7–7.9) | 2.3 (0.9–6.1) | 2.1 (0.9–4.6) | 2.8 (1.0–7.6) | |
| Nausea | 55 (22.0) | 35 (9.9) | 1.3 (0.5–3.3) | 1.7 (0.7–3.9) | 4.0 (0.8–19.1) | ||
| Fatigue | 106 (41.4) | 85 (24.3) | 1.8 (0.7–4.3) | 1.6 (0.6–4.2) | |||
| Headache | 108 (42.2) | 103 (29.3) | 1.5 (1.0–2.1) | 1.2 (0.5–2.8) | 1.9 (0.9–3.8) | 1.5 (0.8–2.6) | 1.1 (0.4–3.4) |
| Loss of appetite | 23 (8.9) | 14 (4.1) | 2.0 (1.0–4.0) | 1.5 (0.4–5.2) | 0.9 (0.2–3.3) | 2.6 (0.3–19.5) | |
| Vomiting | 20 (7.9) | 13 (3.7) | 1.8 (0.9–3.7) | 1.4 (0.4–4.5) | 1.8 (0.5–6.5) | 2.7 (0.6–11.5) | |
| Weight loss | 14 (5.5) | 10 (2.9) | 1.8 (0.8–4.1) | 1.4 (0.3–6.8) | 1.4 (0.2–8.9) | 2.9 (0.5–16.4) | 2.5 (0.5–13.3) |
Bolded values indicate a significant association